Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CerSci Therapeutics
New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.
Many large and growing diseases, such as diabetes, cause vessel damage calling for replacement vascular grafts. The European market for prosthetic vascular grafts is today a $343 million industry and growing, according to "The European Prosthetic Vascular Grafts Market," a report just issued y Medtech Insight.
- Other Names / Subsidiaries
- Acadia Pharmaceuticals Inc.